Agilent Technologies, Inc. (NYSE:A) 44th Annual TD Cowen Health Care Conference March 4, 2024 2:50 PM ET Company Participants Robert McMahon - SVP and CFO Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Great. Here to kick off the Agilent session. I'm Dan Brennan, I cover Tools Diagnostics here. Really pleased to be hosting Bob McMahon, Chief Financial Officer of Agilent here at the 44th Annual TD Cowen Healthcare Conference. So, first off, Bob and Parmeet, welcome. Robert McMahon Than ...

Company Leadership Transition - Mike McMullen, the long-serving CEO of Agilent, is retiring effective May 1st, with Padraig McDonnell set to take over [4][5] - McDonnell has been with Agilent for 26 years and is expected to maintain the company's strong culture while focusing on customer-centricity and growth [6][7] Financial Performance and Outlook - Agilent experienced a slight core growth of 1.4% in fiscal year 2023, with expectations for improvement in 2024, particularly in the pharma sector [8][10] - The first half of 2024 is anticipated to mirror the second half of 2023, with a recovery expected in the pharma area [10][12] - Q1 results showed better-than-expected performance, particularly in China and applied markets [10][14] Market Dynamics - The biotech funding landscape is beginning to recover after challenges in 2023, which is seen as a positive sign for Agilent [9][10] - The company is focusing on biopharma as a key growth area, with expectations for continued emphasis on this sector [7][12] Regional Insights - In China, Agilent's business was down 9% in Q1, which was better than the anticipated mid-20% decline, indicating stabilization in the market [20][22] - The Chemical and Advanced Materials segment is expected to see modest growth, driven by advanced materials rather than chemicals [59][60] Strategic Priorities - Agilent aims to continue expanding into higher growth areas, particularly in biotech and applied markets, while maintaining a strong focus on customer satisfaction and operational execution [65][66] - The company is open to M&A opportunities, particularly in the $1 billion to $2 billion range, to enhance its portfolio [56][65]

Part I [Item 1. Condensed Consolidated Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements%20%28Unaudited%29) Agilent's unaudited Q1 FY2024 financial statements are presented, detailing a segment reorganization - In Q1 2024, the company reorganized its operating segments, moving the cell analysis business from the Life Sciences and Applied Markets segment to the Diagnostics and Genomics segment, with all historical financial segment information recast to conform to this new structure[24](index=24&type=chunk)[142](index=142&type=chunk) [Condensed Consolidated Statement of Operations](index=3&type=section&id=Condensed%20Consolidated%20Statement%20of%20Operations) Agilent reported Q1 FY2024 net revenue of $1,658 million, a decrease from the prior year, with net income remaining stable at $348 million Q1 FY2024 vs. Q1 FY2023 Statement of Operations Highlights (in millions, except per share amounts) | Metric | Three Months Ended Jan 31, 2024 | Three Months Ended Jan 31, 2023 | | :--- | :--- | :--- | | **Total Net Revenue** | $1,658 | $1,756 | | *Products* | $1,209 | $1,323 | | *Services and other* | $449 | $433 | | **Income from Operations** | $384 | $426 | | **Net Income** | $348 | $352 | | **Diluted EPS** | $1.18 | $1.19 | [Condensed Consolidated Balance Sheet](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheet) As of January 31, 2024, Agilent's total assets increased to $10,948 million, while total liabilities decreased to $4,760 million Balance Sheet Summary (in millions) | Metric | January 31, 2024 | October 31, 2023 | | :--- | :--- | :--- | | **Total Current Assets** | $4,338 | $4,186 | | **Total Assets** | $10,948 | $10,763 | | **Total Current Liabilities** | $1,617 | $1,603 | | **Long-term Debt** | $2,555 | $2,735 | | **Total Liabilities** | $4,760 | $4,918 | | **Total Stockholders' Equity** | $6,188 | $5,845 | [Condensed Consolidated Statement of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) Net cash provided by operating activities significantly increased to $485 million in Q1 FY2024, with cash used in investing and financing activities Cash Flow Summary (in millions) | Cash Flow Activity | Three Months Ended Jan 31, 2024 | Three Months Ended Jan 31, 2023 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $485 | $296 | | **Net cash used in investing activities** | $(95) | $(104) | | **Net cash used in financing activities** | $(240) | $(17) | | **Net increase in cash** | $157 | $197 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting policies, segment revenue, restructuring costs, debt, and share repurchase programs Q1 FY2024 Revenue by Segment (in millions) | Segment | Q1 2024 Revenue | Q1 2023 Revenue | | :--- | :--- | :--- | | Life Sciences and Applied Markets | $846 | $943 | | Diagnostics and Genomics | $407 | $432 | | Agilent CrossLab | $405 | $381 | | **Total** | **$1,658** | **$1,756** | - The FY23 Restructuring Plan incurred costs of **$3 million** in Q1 2024, totaling **$49 million** since inception, aiming to reduce workforce and consolidate facilities by end of fiscal 2024[116](index=116&type=chunk)[118](index=118&type=chunk) - The company paid cash dividends of **$0.236 per share** (**$69 million** total) in Q1 2024, with approximately **$1.524 billion** remaining authorized for share repurchases[133](index=133&type=chunk)[134](index=134&type=chunk) - In Q1 2024, the company prepaid **$180 million** on its term loan, reducing the outstanding balance to **$420 million**[127](index=127&type=chunk)[232](index=232&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=40&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a 6% year-over-year decline in Q1 2024 net revenue due to customer capital expenditure pressures, while highlighting strong liquidity and cost-saving strategies [Results of Operations](index=44&type=section&id=MD%26A%20-%20Results%20of%20Operations) Overall net revenue decreased 6% year-over-year to $1,658 million, driven by weakness in Americas and Asia Pacific, while operating margin declined Overall Operating Results (in millions, except margin data) | Metric | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | **Total Net Revenue** | $1,658 | $1,756 | (6)% | | **Total Gross Margin** | 54.8% | 55.1% | (0.3) ppts | | **Operating Margin** | 23.2% | 24.3% | (1.1) ppts | | **Income from Operations** | $384 | $426 | (10)% | - Product revenue declined **9%** year-over-year, primarily due to decreases in liquid chromatography, mass spectrometry, and cell analysis businesses, reflecting customer capital expenditure pressures[177](index=177&type=chunk)[178](index=178&type=chunk) - Services and other revenue grew **4%** year-over-year, driven by strong demand for contract repair and maintenance[177](index=177&type=chunk)[178](index=178&type=chunk) [Segment Overview](index=46&type=section&id=MD%26A%20-%20Segment%20Overview) Life Sciences and Applied Markets and Diagnostics and Genomics segments saw revenue declines, while Agilent CrossLab achieved 6% growth Segment Performance (Q1 FY2024 vs Q1 FY2023, in millions) | Segment | Net Revenue (YoY Change) | Operating Income (YoY Change) | Operating Margin | | :--- | :--- | :--- | :--- | | **Life Sciences & Applied Markets** | $846 (-10%) | $236 (-22%) | 27.9% | | **Diagnostics & Genomics** | $407 (-6%) | $70 (-4%) | 17.3% | | **Agilent CrossLab** | $405 (+6%) | $122 (+19%) | 30.2% | - Life Sciences and Applied Markets experienced significant revenue declines in the pharmaceutical and chemical markets, with weakness in liquid and gas chromatography and mass spectrometry products[180](index=180&type=chunk)[196](index=196&type=chunk) - Diagnostics and Genomics saw a significant revenue decline in the pharmaceutical market due to lower sales in its cell analysis and nucleic acid solutions businesses[181](index=181&type=chunk)[206](index=206&type=chunk) - Agilent CrossLab demonstrated strong revenue growth across all end markets, led by high demand for repair, maintenance, and compliance services[182](index=182&type=chunk)[213](index=213&type=chunk)[215](index=215&type=chunk) [Financial Condition, Liquidity and Capital Resources](index=51&type=section&id=MD%26A%20-%20Financial%20Condition%2C%20Liquidity%20and%20Capital%20Resources) Agilent's liquidity remains strong with increased cash from operations, used for capital expenditures, debt prepayment, and dividends - Net cash provided by operating activities significantly increased to **$485 million** in Q1 2024 from **$296 million** in Q1 2023, mainly due to improved working capital management, including lower inventory cash usage and higher cash from accounts payable[222](index=222&type=chunk)[223](index=223&type=chunk) - The company prepaid **$180 million** of its term loan and paid **$69 million** in dividends, with no shares repurchased during the quarter[227](index=227&type=chunk)[228](index=228&type=chunk)[232](index=232&type=chunk) - Capital expenditures totaled **$90 million**, largely for the expansion of the nucleic acid therapeutics manufacturing facility in Frederick, Colorado, with total expected capex for the year approximately **$400 million**[225](index=225&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=54&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company manages market risks from foreign currency and interest rate fluctuations using derivative instruments, with minimal material impact from hypothetical adverse movements - The company is exposed to foreign currency exchange rate risk, as approximately **54%** of its revenue was generated in non-U.S. dollar currencies in Q1 2024, mitigated by hedging programs[236](index=236&type=chunk)[237](index=237&type=chunk) - A sensitivity analysis indicated that a hypothetical **10%** adverse movement in foreign exchange rates or interest rates would not have a material effect on the company's financial position or results[238](index=238&type=chunk)[239](index=239&type=chunk) [Item 4. Controls and Procedures](index=54&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of January 31, 2024, with no material changes in internal control over financial reporting - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures are effective as of the end of the period[240](index=240&type=chunk) - There were no material changes in the company's internal control over financial reporting during the quarter ended January 31, 2024[241](index=241&type=chunk) Part II [Item 1. Legal Proceedings](index=55&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various lawsuits and claims arising in the ordinary course of business, but does not anticipate a material impact on its financial condition - The company is involved in ordinary course lawsuits and investigations but states there are no pending matters currently believed to be reasonably possible of having a material impact on its business or financials[242](index=242&type=chunk) [Item 1A. Risk Factors](index=55&type=section&id=Item%201A.%20Risk%20Factors) Agilent faces significant risks including global economic sensitivity, intense competition, regulatory compliance, operational disruptions, and financial market volatility - Business is sensitive to global economic conditions, customer spending policies, and geopolitical uncertainties, particularly in China, which can reduce demand and lengthen sales cycles[243](index=243&type=chunk)[249](index=249&type=chunk)[253](index=253&type=chunk) - The company faces significant regulatory risks, including compliance with FDA and foreign agency rules (like EU IVDR), complex data privacy laws (GDPR), and anti-corruption laws (FCPA), with non-compliance potentially leading to fines and business restrictions[268](index=268&type=chunk)[271](index=271&type=chunk)[273](index=273&type=chunk) - Operational risks include dependence on contract manufacturing, potential disruptions at consolidated manufacturing sites, and significant security breaches or failures of critical IT systems[287](index=287&type=chunk)[289](index=289&type=chunk)[294](index=294&type=chunk) - Financial risks include potential adverse effects from changes in tax laws (such as OECD's Pillar Two), the impact of outstanding debt on financial flexibility, and market risks affecting pension plan assets and cash investments[297](index=297&type=chunk)[298](index=298&type=chunk)[301](index=301&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=68&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company has a $2.0 billion share repurchase program, but no shares were repurchased during Q1 FY2024 - The company has a **$2.0 billion** share repurchase program (the "2023 repurchase program")[311](index=311&type=chunk) - No shares were repurchased during the three months ended January 31, 2024, with approximately **$1.524 billion** remaining available for repurchase under the program[312](index=312&type=chunk) [Item 5. Other Information](index=68&type=section&id=Item%205.%20Other%20Information) No officers or directors adopted, modified, or terminated Rule 10b5-1 trading arrangements during the first quarter of fiscal 2024 - During the quarter ended January 31, 2024, no officers or directors adopted, modified, or terminated a Rule 10b5-1 trading arrangement[313](index=313&type=chunk) [Item 6. Exhibits](index=69&type=section&id=Item%206.%20Exhibits) The exhibits filed with the Form 10-Q report include CEO and CFO certifications and Inline XBRL documents for financial data - The exhibits filed with the report include CEO and CFO certifications under Sarbanes-Oxley Sections 302 and 906, and XBRL interactive data files[315](index=315&type=chunk)

Core Insights - Agilent Technologies Inc. has awarded the Agilent Solutions Innovation Research Award (SIRA) to three distinguished professors for their research in advancing energy storage technology [1][2] - The awards highlight the importance of developing new materials for more efficient and durable batteries, addressing environmental issues related to fossil fuel use [1] Group 1: Award Recipients and Their Research - Professors Michel Barsoum and Yury Gogotsi are recognized for their work on nanomaterials for battery applications, specifically the development of MXenes, a new class of 2D materials [2] - Professor Ananda Amarasekara is acknowledged for his research on renewable electrical energy storage technologies and methods for recovering valuable metals from spent Li-ion batteries [2] Group 2: Significance of the Awards - The awards emphasize Agilent's commitment to supporting innovative research that addresses pressing scientific challenges in energy storage and sustainability [3][4] - Agilent's atomic spectroscopy products are positioned as critical tools in advancing research in advanced materials and battery technologies [3] Group 3: Agilent's Business Overview - Agilent Technologies generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people globally [4] - The company provides a comprehensive range of analytical solutions, including instruments, software, and services, aimed at delivering insights and innovation in scientific research [4]

Core Insights - Agilent Technologies reported first-quarter fiscal 2024 earnings of $1.29 per share, exceeding the Zacks Consensus Estimate by 6.6%, but down 6% year-over-year [1] - Revenues reached $1.66 billion, surpassing the Zacks Consensus Estimate of $1.57 billion, yet declined 5.6% on a reported basis and 6.4% on a core basis compared to the previous year [1] - The revenue decline was attributed to widespread weakness across all end markets, particularly in Pharma, Chemistry & Advanced Materials, Food, and Diagnostics and Clinical markets, along with weak momentum in China [1] Segmental Performance - Life Sciences & Applied Markets Group (LSAG) generated $846 million, accounting for 51% of total revenues, down 10% reported and 11% core year-over-year, missing the consensus estimate of $849 million [2] - Agilent Cross Lab Group (ACG) reported revenues of $405 million, representing 24% of total revenues, exceeding the consensus mark of $385 million, with a 6% increase reported and 5% core year-over-year [3] - Diagnostics and Genomics Group (DGG) revenues decreased 6% year-over-year to $407 million, accounting for 25% of total revenues, but surpassed the consensus estimate of $332 million [3] Operating Results - Gross margin in the LSAG segment contracted by 130 basis points to 60.2%, while ACG's gross margin expanded by 200 basis points to 50.5%, and DGG's gross margin increased by 20 basis points to 52.8% [4] - Research and development costs rose to $128 million, up 4.1% year-over-year, while selling, general and administrative expenses decreased to $396 million, down 5.5% year-over-year [4] - The overall operating margin for the quarter was 23.2%, contracting 110 basis points from the previous year, with LSAG's operating margin down 390 basis points to 27.9% [4] Balance Sheet & Cash Flow - As of January 31, 2024, Agilent's cash and cash equivalents increased to $1.75 billion from $1.59 billion as of October 31, 2023 [5] - Accounts receivables were $1.295 billion, slightly up from $1.291 billion at the end of the previous quarter [6] - Long-term debt decreased to $2.555 billion from $2.735 billion in the prior quarter, while cash generated from operations was $485 million, down from $516 million [6] Guidance - For the second quarter of fiscal 2024, management anticipates revenues between $1.560 billion and $1.590 billion, indicating a decline of 9.1-7.4% reported and 8.4-6.7% core year-over-year [7] - Non-GAAP earnings per share are projected to be between $1.17 and $1.20, with the consensus estimate at $1.27 [7] - For fiscal 2024, expected revenues are between $6.710 billion and $6.810 billion, suggesting a decline of 1.8-0.3% reported year-over-year, with non-GAAP earnings per share projected at $5.44-$5.55 [7]

Key TakeawaysAgilent Technologies shares jumped after the company topped analysts' expectations for revenue and profit in its fiscal first quarter amid stabilization in China and secular growth drivers in applied markets.CEO Mike McMullen said that he expects the market environment to undergo a slow and steady improvement in the second half of the year.Agilent shares may encounter overhead chart resistance from prior price action around $141 and $160. Agilent Technologies, Inc. Source: TradingView.com.Sh ...

Agilent Technologies, Inc. (NYSE:A) Q1 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Parmeet Ahuja - Investor Relations Padraig McDonnell - Chief Operating Officer & Chief Executive Officer-elect Mike McMullen - President & Chief Executive Officer Robert McMahon - Senior Vice President & Chief Financial Officer Angelica Riemann - President of Agilent CrossLab Group Phil Binns - President of Agilent Life Sciences & Applied Markets Group Conference Call Participants Derik De ...

For the quarter ended January 2024, Agilent Technologies (A) reported revenue of $1.66 billion, down 5.6% over the same period last year. EPS came in at $1.29, compared to $1.37 in the year-ago quarter.The reported revenue represents a surprise of +5.53% over the Zacks Consensus Estimate of $1.57 billion. With the consensus EPS estimate being $1.21, the EPS surprise was +6.61%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

Agilent Technologies (A) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.21 per share. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.61%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.34 per share when it actually produced earnings of $1.38, delivering a surprise of 2.99%.Over the last four qu ...

Investors are eager for stocks that can keep etching out gains with the S&P 500 and Nasdaq already up over +6% this year following stellar performances for both indexes in 2023.Of course, investors should never get over-consumed with FOMO but several top-rated Zacks stocks look attractive ahead of their quarterly reports on Tuesday, February 27. With representation from a variety of sectors here are three of these top-rated stocks to consider as earnings approach.Agilent Technologies (A) Tech stocks continu ...